Core C: Virology will support Research Projects I, II and III and Cores B and D through the provision ofspecific reagents, antiviral and other anti-infective evaluations, and efficacy data for the pyrimidinediones,ISIS 5320 oligonucleotide, and NCp7 viral inactivating agents alone and in combination products. Core C willaccomplish these goals by implementation of the following objectives:Objective 1: Primary Antiviral Efficacy and Toxicity Testing: The antiviral efficacy and toxicity data will utilizewhole virus replication assays and specific cellular and biochemical assays to measure the antiviral effects ofthe active microbicide and formulated product based on their defined mechanisms of action. Toxicityevaluations will be performed in parallel for each antiviral measurement. Objective 2: Evaluation of theActivity of Combination Microbicide Products:
The aim of this objective is to utilize standard in vitromicrobicide efficacy assays to evaluate, quantify and prioritize combinations of microbicide products to bedeveloped as long-lasting microbicides for evaluation in ex vivo cervical explant models as well as for furtherdevelopment as gel and ring products. Objective 3: Evaluation of the Effects of Vaginal and Seminal Fluidson Viral Infectivity and Microbicide Efficacy and Toxicity: We will perform in vitro efficacy and toxicityevaluations using seminal plasma and vaginal fluid additives to each of the antiviral assays performed and tofurther define the biological properties of these fluids on viral infectivity, microbicide action, and cellulartoxicity.Objective 4: Development of Microbicide-Resistant Virus Strains and Evaluation of the Ability of theMicrobicides to Inhibit the Transmission of Wild Type and Resistant Virus: We will select for viruses that areresistant to each of the microbicides alone and in combination with one another and evaluate the ability ofthe microbicides to totally suppress the transmission of wild type and resistant viruses.Objective 5: ToxicityEvaluation of Microbicide Products and Formulated Materials: Cell-based in vitro toxicology testing will beperformed utilizing cell lines, relevant Lactobacilli species, and ex vivo tissues. Objective 6: PreclinicalDevelopment of Microbicide Products Alone and In Combination: Lead microbicide products defined by thestudies will be assessed for their antiviral potential consistent with their advancement to clinical testing.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI077289-01
Application #
7418075
Study Section
Special Emphasis Panel (ZAI1-CCH-A (S1))
Project Start
2008-06-27
Project End
2013-05-31
Budget Start
2008-06-27
Budget End
2009-05-31
Support Year
1
Fiscal Year
2008
Total Cost
$106,135
Indirect Cost
Name
Imquest Biosciences
Department
Type
DUNS #
146051664
City
Frederick
State
MD
Country
United States
Zip Code
21704
Gao, Yajing; Katz, David F (2017) Multicompartmental Pharmacokinetic Model of Tenofovir Delivery to the Rectal Mucosa by an Enema. PLoS One 12:e0167696
Funke, Claire; MacMillan, Kelsey; Ham, Anthony et al. (2016) Coupled gel spreading and diffusive transport models describing microbicidal drug delivery. Chem Eng Sci 152:12-20
Gao, Y; Yuan, A; Chuchuen, O et al. (2015) Vaginal deployment and tenofovir delivery by microbicide gels. Drug Deliv Transl Res 5:279-94
Katz, David F; Yuan, Andrew; Gao, Yajing (2015) Vaginal drug distribution modeling. Adv Drug Deliv Rev 92:2-13
Morrow Guthrie, Kate; Vargas, Sara; Shaw, Julia G et al. (2015) The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development. PLoS One 10:e0145642
Rosen, Rochelle K; van den Berg, Jacob J; Vargas, Sara E et al. (2015) Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings. Contraception 92:596-601
Ugaonkar, Shweta R; Clark, Justin T; English, Lexie B et al. (2015) An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. J Pharm Sci 104:3426-39
van den Berg, Jacob J; Rosen, Rochelle K; Bregman, Dana E et al. (2014) ""Set it and forget it"": women's perceptions and opinions of long-acting topical vaginal gels. AIDS Behav 18:862-70
Tolley, Elizabeth E; Morrow, Kathleen M; Owen, Derek H (2013) Designing a multipurpose technology for acceptability and adherence. Antiviral Res 100 Suppl:S54-9
Rastogi, Rachna; Teller, Ryan S; Mesquita, Pedro M M et al. (2013) Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res 100:255-8

Showing the most recent 10 out of 25 publications